Chinese APIs flowing but India ban hinders U.S. approval of hydroxychloroquine

31st March 2020 Uncategorised 0

The production of Chinese active pharmaceutical ingredients (APIs) slipped by 10% to 20% during the early days of the COVID-19 outbreak in China but is quickly recovering. The bottleneck in the global supply chain for APIs is now shipping, particularly ocean freight. 

More: Chinese APIs flowing but India ban hinders U.S. approval of hydroxychloroquine
Source: fierce